← Back to Search

Liposomal Curcumin + RT/TMZ for Brain Tumor

Phase 1 & 2
Recruiting
Led By Matthias Holdhoff, MD, PhD
Research Sponsored by SignPath Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the duration of treatment for each patient up to 34 weeks
Awards & highlights

Summary

This trial tests a new treatment combining a special form of curcumin with radiation and chemotherapy for patients with aggressive brain tumors. The goal is to improve curcumin absorption and enhance the effects of standard treatments.

Who is the study for?
Adults over 18 with newly diagnosed High-Grade Gliomas, including GBM and other types, suitable for RT/TMZ treatment. Must have good organ function, not be pregnant or breastfeeding, no recent heart issues or active infections requiring antibiotics. HIV-positive patients can join if undetectable viral load. Participants must agree to use contraception.
What is being tested?
The trial is testing the safety and effectiveness of Liposomal Curcumin (LC) when used alongside standard radiotherapy (RT) and Temozolomide (TMZ). The study will observe how well patients tolerate this combination therapy during different treatment periods: adjuvant, post-CRT, and concurrent CRT.
What are the potential side effects?
Potential side effects may include reactions similar to those from compounds like LC such as allergic responses. Other risks could involve typical chemotherapy-related side effects like fatigue, digestive problems, blood disorders but specific side effect profiles of LC will be monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the duration of treatment for each patient up to 34 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and the duration of treatment for each patient up to 34 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The number of observed Dose Limiting Toxicity (DLTs)
Secondary study objectives
Overall Survival (OS)
Progression free survival (PFS)
The incidence of Adverse Events
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tolerability, Safety, and Efficacy of LC in Combination with RT and TMZExperimental Treatment3 Interventions
Define the MTD/recommended Phase 2 dose (RP2D) of LC, administered IV weekly in combination with standard CRT (60 Gy in 30-33 fractions M-F, and daily oral TMZ 75 mg/m2), in patients with high grade malignant gliomas. This study seeks the MTD/RP2D of LC when added to TMZ during concurrent RT and adjuvant TMZ after RT. The study will evaluate escalating doses of LC delivered by IV infusion weekly as a gravity infusion (without infusion pump). Within each cohort, the dose will remain the same. In the first cohort, dosing will begin at Level 1 (300 mg/m2). The infusion of LC will begin at the start of CRT. Patients will be evaluable for the cohort if they have completed 80% of the planned doses of LC, 80% of RT and 60% of TMZ within the first 10 weeks of treatment. Patients who experience a dose-limiting toxicity (DLT) will be evaluable for the cohort if they have received at least 1 dose of LC.

Find a Location

Who is running the clinical trial?

Avance ClinicalUNKNOWN
3 Previous Clinical Trials
167 Total Patients Enrolled
SignPath Pharma, Inc.Lead Sponsor
2 Previous Clinical Trials
80 Total Patients Enrolled
Avance Clinical Pty Ltd.Industry Sponsor
15 Previous Clinical Trials
3,091 Total Patients Enrolled
1 Trials studying Glioblastoma
48 Patients Enrolled for Glioblastoma

Media Library

Radiotherapy Clinical Trial Eligibility Overview. Trial Name: NCT05768919 — Phase 1 & 2
Glioblastoma Research Study Groups: Tolerability, Safety, and Efficacy of LC in Combination with RT and TMZ
Glioblastoma Clinical Trial 2023: Radiotherapy Highlights & Side Effects. Trial Name: NCT05768919 — Phase 1 & 2
Radiotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05768919 — Phase 1 & 2
~14 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top